FDA Weighs In On Gilead's Crucial Pill - Forbes

The Quad is a once-a-day pill that aims to provide Gilead with a revenue stream that will last beyond the patent expiration of its key drug Viread and its current one-a-day, Atripla. The Quad also represents a real threat to Merck‘s Isentress.

HIV Drug Maker Gilead Sciences Scores Two Wins - Minyanville

The stock is up more than 6% since last Tuesday. In studies, Gilead showed that Quad worked at least as well as the company’s top-selling Atripla and was as safe as that drug. There are concerns about Quad’s effect on kidneys, which would ...

AIDS Advocates to Protest Gilead over Drug Pricing at May 10th Shareholders’ Meeting - StreetInsider.com

“The nation’s network of AIDS Drug Assistance Programs face desperate circumstances because of high prices for drugs like Gilead’s Atripla—and, soon, the ‘Quad.’ As a healthcare provider and advocacy group, AIDS Healthcare Foundation will ...

A Step Closer to Quadrific Sales - Motley Fool

The extra kidney test might make it harder to get doctors to prescribe the Quad over Atripla, but the Quad has other advantages, including fewer abnormal dreams, less trouble sleeping, and less dizziness compared with Atripla. Kidney issues are ...

Sen. Bernie Sanders holds hearing to announce $3 billion AIDS drug prize - Raw Story

Raw Story spoke with Sanders’s chief counsel and legislative director Michael Behan, who cited the example of Atripla, a combination drug used to fight HIV. Currently, the drug retails at more than $25,000 per year per person. “Witnesses at ...

Good News for Gilead - Analyst Blog - NASDAQ

We remain optimistic on the growth prospects of Gilead's HIV drugs, Truvada and Atripla. We are also encouraged by the approval of Complera/Eviplera, which together with Quad, once approved, will further fortify the HIV franchise and help ...

FDA Advisory Committee Supports Approval of Gilead’s Once-Daily Quad Single Tablet Regimen for HIV - Yahoo Finance

The Quad NDA is supported by the positive results from two pivotal Phase 3 studies in which Quad met its primary objective of non-inferiority as compared to Atripla ® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg ...

Gilead Sciences 1Q profit down on Pharmasset costs - MySanAntonio

Analysts expect it to become a bigger health problem as baby boomers age. Gilead said sales of its HIV drug Atripla rose 19 percent to $887.6 million. Sales of Truvada grew 13 percent to $758.3 million and revenue from Viread increased 14 percent to $191.7 million.

Gilead Sciences HIV Drug Quad Gets FDA Panel Backing - NASDAQ

Currently, Gilead's Atripla is the most-prescribed HIV treatment regimen in the US. For the first quarter of 2012, Atripla sales increased 19 percent to $887.6 million, while sales from Truvada, another HIV drug, increased 13 percent to $758.3 million.

Op-ed: Riding Is Like Choosing to Live - Advocate

I spent that next month in the hospital. Five years or so later he changed my cocktail regimen to Atripla, and I have been on it ever since. The next nine years were spent waiting to die. Two years ago, a friend of mine was training for AIDS ...